Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLOD2 | O00469 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.56 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
| ▸ | F3 | P13726 | 1/20 | 0.47 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819978 | 0.86 | PLOD2 (0.58) | PLOD2ALDH1A1PLOD3PLOD1KMT2A | |
| SCHEMBL82139 | 0.83 | PLOD2 (0.67) | PLOD2ALDH1A1PLOD3PLOD1KMT2A | |
| SCHEMBL30489909 | 0.83 | PLOD2 (0.67) | PLOD2ALDH1A1PLOD3PLOD1KMT2A | |
| SCHEMBL29554726 | 0.82 | PLOD2 (0.89) | PLOD2ALDH1A1PLOD3PLOD1KMT2A | |
| SCHEMBL10320930 | 0.82 | PLOD2 (0.89) | PLOD2ALDH1A1PLOD3PLOD1KMT2A | |
| Hydrochloric Acid SCHEMBL6946997 | 0.82 | PLOD2 (0.65) | PLOD2ALDH1A1PLOD3PLOD1KMT2A | |
| SCHEMBL21828675 | 0.82 | PLOD2 (0.56) | PLOD2ALDH1A1PLOD3PLOD1KMT2A | |
| SCHEMBL21828681 | 0.82 | PLOD2 (0.56) | PLOD2ALDH1A1PLOD3PLOD1KMT2A | |
| SCHEMBL1062957 | 0.80 | PLOD2 (0.56) | PLOD2ALDH1A1PLOD3PLOD1KMT2A | |
| SCHEMBL30489910 | 0.80 | PLOD2 (0.71) | PLOD2ALDH1A1PLOD3PLOD1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421210-B2 | Fused bicyclic heterocycles as therapeutic agents | NEW YORK UNIVERSITY (US) | 2025-09-23 | — | — | US | disclosed |
| EP-3856735-B1 | FUSED BICYCLIC HETEROCYCLES AS THERAPEUTIC AGENTS | UNIV NEW YORK (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230012463-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2023-01-12 | — | — | US | disclosed |
| US-20210395222-A1 | Fused Bicyclic Heterocycles as Therapeutic Agents | NEW YORK UNIVERSITY | 2021-12-23 | — | — | US | disclosed |
| EP-3856735-A1 | FUSED BICYCLIC HETEROCYCLES AS THEREAPEUTIC AGENTS | New York University (US) | 2021-08-04 | — | — | EP | disclosed |
| US-11078170-B2 | Cyclic sulfamide compounds and methods of using same | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11078170-B2 | Cyclic sulfamide compounds and methods of using same | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3589630-B1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3589630-B1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2021-07-07 | — | — | EP | disclosed |
| US-20200157070-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2020-05-21 | — | — | US | disclosed |
| EP-1534683-A4 | CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2005-08-24 | — | — | EP | disclosed |
| EP-1534683-A2 | CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040053985-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. | 2004-03-18 | — | — | US | disclosed |
| WO-2004002409-A2 | CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-4315932-A | AND SULFANILAMIDES | BURROUGHS WELLCOME CO. (US) | 1982-02-16 | — | — | US | disclosed |
| EP-0000541-B1 | 1H-PYRIMIDO-(4,5-C)-1,2-DIAZEPINES, METHODS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM; THEIR USE AS INTERMEDIATES FOR HETEROCYCLIC TRANSFORMATIONS. | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-02-03 | — | — | EP | disclosed |
| US-4288365-A | 1H-PYRIMIDO(4,5-C)-1,2-DIAZEPINES | BURROUGHS WELLCOME CO. (US) | 1981-09-08 | — | — | US | disclosed |
| US-4260758-A | MICROBIOCIDES | BURROUGHS WELLCOME CO. (US) | 1981-04-07 | — | — | US | disclosed |
| US-4237289-A | MICROBIOCIDES | BURROUGHS WELLCOME CO. (US) | 1980-12-02 | — | — | US | disclosed |
| EP-0000541-A2 | 1H-Pyrimido-(4,5-c)-1,2-diazepines, methods for their preparation and compositions containing them; their use as intermediates for heterocyclic transformations. | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053985-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGES2 | PLOD2 1406/4885ALDH1A1 638/4885PLOD3 3916/4885 |
| US-12421210-B2 | Fused bicyclic heterocycles as therapeutic agents | NAMPT, NQO1, NAPRT | PLOD2 4301/4885ALDH1A1 1562/4885PLOD3 2309/4885 |
| US-20210395222-A1 | Fused Bicyclic Heterocycles as Therapeutic Agents | NAMPT, NQO1, NAPRT | PLOD2 4301/4885ALDH1A1 1562/4885PLOD3 2309/4885 |
| US-20230012463-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | HCCS, HAVCR2, SLC10A1 | PLOD2 3999/4885ALDH1A1 4068/4885PLOD3 2301/4885 |
| US-11078170-B2 | Cyclic sulfamide compounds and methods of using same | HCCS, HAVCR2, SLC10A1 | PLOD2 3999/4885ALDH1A1 4068/4885PLOD3 2301/4885 |
| US-20200157070-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | HCCS, HAVCR2, SLC10A1 | PLOD2 3999/4885ALDH1A1 4068/4885PLOD3 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.